Compositions and methods for treating antiphospholipid syndrome
AssigneeBeth Israel Deconess Medical Center, Inc.
InventorNatalia BEGLOVA
Life of this patent
Estimating the term…
Abstract
The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target β2GPI in β2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.
Claims21
1-32. (canceled)
A polypeptide comprising a first A1 domain of apolipoprotein E receptor 2 (ApoER2), wherein said A1 domain is the first low density lipoprotein (LDL) receptor-type A (LA) module of said ApoER2, a second A1 domain of said ApoER2, and a linker that joins said first A1 domain to said second A1 domain.
A polypeptide comprising a first low density lipoprotein (LDL) receptor-type A (LA) module, a second LA module, and a linker that joins said first LA module to said second LA module;
- wherein said first LA module comprises a first A1 domain comprising an amino acid sequence with 85% or more sequence identity to the amino acid sequence of SEQ ID NO:
- 2, 3, 14, or 15;
- said second LA module comprises a second A1 domain comprising an amino acid sequence with 85% or more sequence identity to the amino acid sequence of SEQ ID NO:
- 2, 3, 14, or 15;
- and
- said polypeptide specifically binds to first and second β2GPI monomers in a dimeric β2GPI/antibody complex.
Dependencies are inferred from the claim text.